Possible Role of Chloroquine to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial
Study Details
Study Description
Brief Summary
The gold-standard treatment of Autoimmune hepatitis (AIH), with prednisone alone or in conjunction with azathioprine can reach resolution of the disease in 70-80% of the cases in US. However, in Brazil the response to these treatments seems to be worse, approximately 35% in five years. Because of the side effects of the gold-standard treatment and the need for an alternative option for the no responsive patients, news drugs must be evaluated for this proposal. Chloroquine diphosphate is an antimalarial drug that has been used for the treatment of rheumatological diseases for at the least five decades. Chloroquine was used as a single drug for up to two years for the maintenance of AIH remission in an open study. There was a 6.49 greater chance of relapse in the historical controls when compared with patients treated with chloroquine (72.2% x 23.5%; p = 0.031). The aim of this study was to investigate whether chloroquine in conjunction with prednisone can be used as an alternative treatment of AIH in a randomized study, and to evaluate its side effects.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
Autoimmune hepatitis (AIH) is a chronic disease with a progressive destruction of hepatic parenchyma, leading to cirrhosis and high mortality in the absence of specific treatment. It has been demonstrated that the treatment with corticosteroids and azathioprine provides clinical and laboratory improvement, reduction of histological inflammatory activity on liver biopsy and an increased survival.
Because of the side effects of the gold-standard treatment and the need for an alternative option for the no responsive patients, news drugs must be evaluated for this proposal.
Chloroquine is a drug of the group of 4-aminoquinolines, synthetic derivatives of quinine and constituent of the bark of the Cinchona tree. Chloroquine accumulates in tissues in considerable amounts. In animals, from 200 to 700 times the plasma concentration can be found in liver, spleen, kidneys and lungs. As a weak base, it accumulates intracellularly, particularly in lysosomes with a consequent increase in pH within these organelles, which could contribute to its toxicity. Lysosomal lamellar bodies are observed in tissues affected by chloroquine, such as retina and neuromuscular system. Chloroquine inhibits the absorption and the binding of mitochondrial calcium, alters the membrane permeability and the transport of enzymes to the lysosomes. Apparently there are other mechanisms to explain its anti-inflammatory action; such as the interference with the release of TNF from mononuclear phagocytes by inhibiting gene expression and the down-regulation of TNF receptors, by delaying their transport to the cellular surface. Due to these mechanisms of action, chloroquine has anti-inflammatory activities and therefore is used in diseases such as rheumatoid arthritis and systemic lupus erythematosus. In liver diseases, chloroquine was used in patients with hepatitis B with normalization of the levels of aminotransferases and of the prothrombin time during treatment and relapse after drug discontinuation. Chloroquine was also evaluated in patients with porphyria cutanea tarda and despite the clinical and biochemical improvement, liver biopsies remained unchanged after one year of treatment.
A previous pilot study was performed in our institution, and published in 2005, with chloroquine diphosphate for the maintenance treatment of AIH. In this study, 14 patients with a biochemical and histological remission were treated with chloroquine diphosphate 250 mg/day for at least 12 months or until disease recurrence, and compared with 18 historical controls, which was held in discontinuation of treatment after remission. The chance of relapse was 6.49 times higher in the historical controls when compared with patients in the group treated with chloroquine (72.2% versus 23.5%, p = 0.031). The use of chloroquine was safe in patients with liver cirrhosis without decompensation, and there were no serious adverse events within two years of use.
The most common adverse effects of chloroquine are mild and transient such as gastrointestinal symptoms, headache, dizziness, blurry vision and fatigue. The more severe reactions described are itching, cardiovascular manifestations, dyskinesias, eye injuries, neuromuscular disorders and hearing loss. Among the most feared adverse effects of chloroquine, are the eye injuries, usually associated with chronic treatment. They may consist of changes in the retina, lens, cornea and optic nerve. Usually they remain stable after drug withdrawal, if the drug is discontinued in early stages. However, the retinal damage can increase when found in advanced stages, and may progress even years after cessation of chloroquine. It is believed that the chloroquine retinopathy can be prevented or recognized in an early reversible stage with judicious use, appropriate doses and regular ophthalmologic follow-up. It is recommended that the daily dose does not exceed 250 mg of chloroquine diphosphate or 400 mg of hydroxychloroquine, and ophthalmologic evaluations are carried out every 4 to 6 months. Despite the adverse effects and toxic reactions described above, there is a consensus in most studies with chloroquine that it is a well tolerated drug, provided that the appropriate dosage guidelines and regular eye examinations are followed. With these cautions in mind, its use rarely causes serious side or irreversible effects.
The aim of this study was to investigate whether chloroquine in conjunction with prednisone can be used as an alternative treatment of AIH in a randomized study, and to evaluate its side effects.
To be included patients had to satisfy the following criteria simultaneously: a diagnosis of probable / definite AIH and the indication of treatment (according to the International AIH Group), normal liver function and absence of clinical signs of decompensated liver disease (ascites, hepatic encephalopathy, gastrointestinal bleeding and hepatocellular carcinoma). For their enrollment, it is necessary that the patients are in accordance with the proposed study, following the precepts of the Declaration of Helsinki. If patients refuse to participate in the study, they will be treated following the traditional guidelines of our service. Treatment will be discontinued in case of pregnancy, patient's desire, side-effects or relapse of AIH.
Patients were randomized to receive azathioprine and prednisone or chloroquine and prednisone. The alternative treatment, with chloroquine, was maintained unless it caused major side-effects, no biochemical response or treatment failure. In this case, azathioprine was introduced in association with prednisone. All patients had visits every 30 days during the first six months with routine blood tests performed. After then, consultations were every two months. All complaints were recorded. Every patient were treated by the doctors responsible for the study, laboratory tests were performed in the Central Laboratory of the hospital. All patients underwent to initial ophthalmologic evaluation followed by six-monthly evaluations. The drug was withdrawal, if changes suggestive of retinopathy were observed.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: chloroquine plus prednisone Chloroquine diphosphate 250mg/day associated to prednisone in variable doses |
Drug: Chloroquine diphosphate
One pill of chloroquine diphosphate per day until the end of the study
Other Names:
Drug: prednisone
Prednisone 5-15 mg/day until the end of the study
|
| Experimental: azathioprine plus prednisone azathioprine in variable doses (50-150mg/day) associated to prednisone in variable doses |
Drug: prednisone
Prednisone 5-15 mg/day until the end of the study
Drug: azathioprine
azathioprine 1-2mg/Kg/day until the end of the study
|
Outcome Measures
Primary Outcome Measures
- Biochemical Response to Therapy [six months]
The biochemical response is defined when there is normalization of hepatic enzymes, mainly AST and ALT.
Secondary Outcome Measures
- Histopathological Response to Therapy [liver biopsy was was performed to evaluate histopathological response after 18 months of biochemical response]
Histopathological response is achieved when there is minimal or no inflammation in hepatic tissue, as assessed by liver biopsy.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosis of autoimmune hepatitis according to Autoimmune Hepatitis International Group with indication for treatment
-
No evidence of decompensated liver cirrhosis
-
Non-pregnant women and women with no intention to become pregnant
-
Willing to participate in the study
Exclusion Criteria:
-
Discrete biochemical changes and histological inflammatory activity absent / minimal (periportal / peri-septal: 0/1 +) or decompensated cirrhosis
-
Cases of loss of follow up
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- University of Sao Paulo General Hospital
Investigators
- Principal Investigator: Eduardo LR Cançado, University of Sao Paulo General Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 0571/04
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Chloroquine Plus Prednisone | Azathioprine Plus Prednisone |
|---|---|---|
| Arm/Group Description | Chloroquine diphosphate 250mg/day associated to prednisone in variable doses Chloroquine diphosphate: One pill of chloroquine diphosphate per day until the end of the study prednisone: Prednisone 5-15 mg/day until the end of the study | azathioprine in variable doses (1-2mg/Kg/day) associated to prednisone in variable doses prednisone: Prednisone 5-15 mg/day until the end of the study azathioprine: azathioprine 1-2mg/Kg/day until the end of the study |
| Period Title: Overall Study | ||
| STARTED | 26 | 31 |
| COMPLETED | 10 | 25 |
| NOT COMPLETED | 16 | 6 |
Baseline Characteristics
| Arm/Group Title | Chloroquine Plus Prednisone | Azathioprine Plus Prednisone | Total |
|---|---|---|---|
| Arm/Group Description | Chloroquine diphosphate 250mg/day associated to prednisone in variable doses Chloroquine diphosphate: One pill of chloroquine diphosphate per day until the end of the study prednisone: Prednisone 5-15 mg/day until the end of the study | azathioprine in variable doses (50-150mg/day) associated to prednisone in variable doses prednisone: Prednisone 5-15 mg/day until the end of the study azathioprine: azathioprine 1-2mg/Kg/day until the end of the study | Total of all reporting groups |
| Overall Participants | 26 | 31 | 57 |
| Age (years) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [years] |
37.54
(15.99)
|
37.23
(17.63)
|
37.28
(16.84)
|
| Gender (Count of Participants) | |||
| Female |
21
80.8%
|
24
77.4%
|
45
78.9%
|
| Male |
5
19.2%
|
7
22.6%
|
12
21.1%
|
Outcome Measures
| Title | Biochemical Response to Therapy |
|---|---|
| Description | The biochemical response is defined when there is normalization of hepatic enzymes, mainly AST and ALT. |
| Time Frame | six months |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Chloroquine Plus Prednisone | Azathioprine Plus Prednisone |
|---|---|---|
| Arm/Group Description | Chloroquine diphosphate 250mg/day associated to prednisone in variable doses Chloroquine diphosphate: One pill of chloroquine diphosphate per day until the end of the study prednisone: Prednisone 5-15 mg/day until the end of the study | azathioprine in variable doses (1-2mg/Kg/day) associated to prednisone in variable doses prednisone: Prednisone 5-15 mg/day until the end of the study azathioprine: azathioprine 1-2mg/Kg/day until the end of the study |
| Measure Participants | 26 | 31 |
| Count of Participants [Participants] |
14
53.8%
|
21
67.7%
|
| Title | Histopathological Response to Therapy |
|---|---|
| Description | Histopathological response is achieved when there is minimal or no inflammation in hepatic tissue, as assessed by liver biopsy. |
| Time Frame | liver biopsy was was performed to evaluate histopathological response after 18 months of biochemical response |
Outcome Measure Data
| Analysis Population Description |
|---|
| The histological response was only evaluated in the patients with biochemical remission, since in the patients without biochemical response it was already known that there would be activity in the liver tissue. |
| Arm/Group Title | Chloroquine Plus Prednisone | Azathioprine Plus Prednisone |
|---|---|---|
| Arm/Group Description | Chloroquine diphosphate 250mg/day associated to prednisone in variable doses Chloroquine diphosphate: One pill of chloroquine diphosphate per day until the end of the study prednisone: Prednisone 5-15 mg/day until the end of the study | azathioprine in variable doses (1-2mg/Kg/day) associated to prednisone in variable doses prednisone: Prednisone 5-15 mg/day until the end of the study azathioprine: azathioprine 1-2mg/Kg/day until the end of the study |
| Measure Participants | 14 | 21 |
| Count of Participants [Participants] |
4
15.4%
|
10
32.3%
|
Adverse Events
| Time Frame | ||||
|---|---|---|---|---|
| Adverse Event Reporting Description | ||||
| Arm/Group Title | Chloroquine Plus Prednisone | Azathioprine Plus Prednisone | ||
| Arm/Group Description | Chloroquine diphosphate 250mg/day associated to prednisone in variable doses Chloroquine diphosphate: One pill of chloroquine diphosphate per day until the end of the study prednisone: Prednisone 5-15 mg/day until the end of the study | azathioprine in variable doses (1-2mg/Kg/day) associated to prednisone in variable doses prednisone: Prednisone 5-15 mg/day until the end of the study azathioprine: azathioprine 1-2mg/Kg/day until the end of the study | ||
All Cause Mortality |
||||
| Chloroquine Plus Prednisone | Azathioprine Plus Prednisone | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | / (NaN) | / (NaN) | ||
Serious Adverse Events |
||||
| Chloroquine Plus Prednisone | Azathioprine Plus Prednisone | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 6/26 (23.1%) | 0/31 (0%) | ||
| Eye disorders | ||||
| machulopatia | 6/26 (23.1%) | 0/31 (0%) | ||
Other (Not Including Serious) Adverse Events |
||||
| Chloroquine Plus Prednisone | Azathioprine Plus Prednisone | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 3/26 (11.5%) | 2/31 (6.5%) | ||
| Gastrointestinal disorders | ||||
| gastric intolerance | 0/26 (0%) | 1/31 (3.2%) | ||
| Nervous system disorders | ||||
| neuropathy | 1/26 (3.8%) | 0/31 (0%) | ||
| Skin and subcutaneous tissue disorders | ||||
| hyperpigmentation | 2/26 (7.7%) | 1/31 (3.2%) | ||
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Lydia Teófilo de Moraes Falcão |
|---|---|
| Organization | Clinic Hospital of University of Sao Paulo |
| Phone | 55-81-996486935 ext 81 |
| lydiatmf@yahoo.com.br |
- 0571/04